Compare INFU & MDWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INFU | MDWD |
|---|---|---|
| Founded | 2005 | 2000 |
| Country | United States | Israel |
| Employees | 473 | 121 |
| Industry | Medical/Dental Instruments | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 196.1M | 193.3M |
| IPO Year | 2005 | 2013 |
| Metric | INFU | MDWD |
|---|---|---|
| Price | $9.54 | $15.05 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | $15.00 | ★ $36.00 |
| AVG Volume (30 Days) | ★ 110.3K | 65.7K |
| Earning Date | 05-07-2026 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 181.82 | N/A |
| EPS | ★ 0.31 | N/A |
| Revenue | ★ $143,436,000.00 | N/A |
| Revenue This Year | $2.89 | $48.88 |
| Revenue Next Year | $7.66 | $35.08 |
| P/E Ratio | $31.29 | ★ N/A |
| Revenue Growth | ★ 6.36 | N/A |
| 52 Week Low | $4.61 | $14.14 |
| 52 Week High | $11.04 | $22.51 |
| Indicator | INFU | MDWD |
|---|---|---|
| Relative Strength Index (RSI) | 54.53 | 31.36 |
| Support Level | $8.52 | N/A |
| Resistance Level | $9.83 | $18.58 |
| Average True Range (ATR) | 0.36 | 0.59 |
| MACD | -0.03 | -0.15 |
| Stochastic Oscillator | 60.22 | 10.15 |
InfuSystems Holdings Inc is a health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers. The company's services are provided under two-reportable segments: Patient Services and Device Solutions. Maximum revenue is generated from its Patient Services segment, which provides Durable Medical Equipment (DME) and treatment consumables, handles order and delivery logistics, provides 24/7 nursing support relating to the provided equipment, assumes responsibility for third-party payer Durable Medical Equipment billing, and handles biomedical services for the Durable Medical Equipment. The Device Solutions segment includes equipment rental and sales, consumable sales, and biomedical support services.
MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid, is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.